Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Preston M Schneider"'
Autor:
Paul S. Chan, Mintu P. Turakhia, Babatunde O. Ogunnaike, Wenhui Liu, Gary K. Grunwald, Comilla Sasson, Preston M. Schneider, P. Michael Ho, Paul D. Varosy, Brahmajee K. Nallamothu, Steven M. Bradley
Publikováno v:
Journal of the Minneapolis Heart Institute Foundation. 2:7-14
Biphasic waveform defibrillators permit effective defibrillation of ventricular tachycardia and ventricular fibrillation (VT/VF) at lower energies. Little data is available on trends in th...
Autor:
Preston M Schneider, Abu Minhajuddin, Steven M. Bradley, Emily Melikman, Girish P. Joshi, Charles W. Whitten, Tiffany S. Moon, Babatunde O. Ogunnaike
Publikováno v:
Resuscitation. 105
Due to higher transthoracic impedance, obese patients may be less likely to be successfully defibrillated from ventricular tachycardia or ventricular fibrillation (VT/VF) arrest. However, the association between patient body mass index (BMI), defibri
Autor:
Paul D. Varosy, Preston M Schneider, Ryan G. Aleong, Paul A. Heidenreich, Cara N. Pellegrini, Pamela N. Peterson, Barry M. Massie, Edmund C. Keung
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 8
Introduction: Dual chamber ICD implantation has been associated with higher complication rates than single chamber ICD implantation without associated decrease in morbidity or mortality in prior reports. If this association is present using validated
Autor:
Kalpana Gupta, Anna E. Barón, Paul D. Varosy, Preston M Schneider, Maggie A. Stanislawski, Judith Strymish, Westyn Branch-Elliman, Howard S. Gold, Michael Ho
Publikováno v:
Open Forum Infectious Diseases. 2
Autor:
Preston M Schneider, Paul S. Chan, Brahmajee K. Nallamothu, Monique L Anderson, Wenhui Liu, Paul D. Varosy, Steven M. Bradley, Gary K. Grunwald, P. Michael Ho, Comilla Sasson
Publikováno v:
Circulation. 130
Background: Among patients with cardiac arrest due to ventricular tachycardia or ventricular fibrillation (VT/VF), guidelines emphasize single shock protocols to minimize interruptions in chest compressions that may impair patient outcomes. The adopt
Autor:
Preston M Schneider, Mintu P. Turakhia, Babatunde O. Ogunnaike, Paul S. Chan, Wenhui Liu, Paul D. Varosy, Brahmajee K. Nallamothu, Steven M. Bradley, Comilla Sasson, Gary K. Grunwald
Publikováno v:
Circulation. 130
Background: Biphasic waveforms have become the predominant choice for defibrillation of cardiac arrest due to pulseless ventricular tachycardia or ventricular fibrillation (VT/VF). However, little is known about the relative efficacy of different fir
Autor:
Preston M Schneider, Wenhui Liu, Brahmajee K. Nallamothu, Mintu P. Turakhia, Paul D. Varosy, P. Michael Ho, Comilla Sasson, Gary K. Grunwald, Paul S. Chan, Steven M. Bradley
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 7
Background: Early defibrillation for termination of life-threatening arrhythmias is key to survival of cardiac arrest. Biphasic waveform defibrillation has been suggested as superior to monophasic waveform defibrillation, but little is known about tr
Autor:
Preston M Schneider, Heather M Tavel, Daniel M Witt, Yardlee S Kauffman, Susan M Shetterly, Alan S Go, P M Ho, David J Magid
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 7
Background: There is uncertainty about the benefits of anticoagulation therapy for stroke reduction in CKD patients with atrial fibrillation. Accordingly, we assessed the association between anticoagulation use and stroke risk in CKD patients with at
Autor:
P. Michael Ho, Anthony A. Bavry, Robert E. Burke, Paul A. Heidenreich, Anna E. Barón, Thomas M. Maddox, Timothy W. Hegeman, John S. Rumsfeld, Kreton Mavromatis, Thomas J. Glorioso, Steven M. Bradley, Preston M Schneider
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 7
Background: 30-day readmission after percutaneous coronary intervention (PCI) is a common, expensive and potentially preventable problem. The relationship between 30-day readmission and long-term patient outcomes has not been studied within integrate
Autor:
Gary K. Grunwald, Supriya Shore, Thomas M. Maddox, Louise Pilote, Mintu P. Turakhia, Paul D. Varosy, Lucas N. Marzec, John S. Rumsfeld, P. Michael Ho, Evan P. Carey, Preston M Schneider, Cynthia A. Jackevicius, Steven M. Bradley, Anna E. Barón, Fran Cunningham
Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed8b30d9fc136d9186e2beaed4e34a56
https://europepmc.org/articles/PMC5381802/
https://europepmc.org/articles/PMC5381802/